Abstract:HIV infection is associated with gut dysbiosis and immune dysfunction. This association is irreversible despite antiretroviral therapy and is commonly found in people living with HIV (PWH) who were treated during chronic infection. To investigate this link in a subpopulation of PWH, HIV controllers (HCs), and its association with viral outcomes, we used metagenomic sequencing to understand fecal microbiome composition in HCs in a study investigating the effect of the TLR7 agonist vesatolimod with a 24‐week antiretroviral treatment interruption (ATI). We found that the abundance of specific phyla in the fecal microbiome of people with HIV correlated with markers of immune activation and that certain microbiota also correlated with time to HIV‐1 rebound or HIV control following ATI. The data from this study support the idea that the relative abundances of some microbiome composition may modulate immune function toward either an anti‐ or pro‐inflammatory response and a possible mechanism to account for ATI viral outcomes in HCs. HIV infection is associated with gut dysbiosis, and microbiome variability may affect HIV control when antiretroviral therapy (ART) is stopped. The TLR7 agonist, vesatolimod, was previously associated with a modest delay in viral rebound following analytical treatment interruption in HIV controllers (HCs). Using a retrospective analysis of fecal samples from HCs treated with vesatolimod or placebo (NCT03060447), people with chronic HIV (CH; NCT02858401) or without HIV (PWOH), we examined fecal microbiome profile in HCs before/after treatment, and in CH and PWOH. Microbiome diversity and abundance were compared between groups to investigate the association between specific phyla/species, immune biomarkers, and viral outcomes during treatment interruption. Although there were no significant differences in gut microbiome diversity between people with and without HIV, HCs, and CH shared common features that distinguished them from PWOH. there was a trend toward greater microbiome diversity among HCs. Treatment with vesatolimod reduced dysbiosis in HCs. Firmicutes positively correlated with T‐cell activation, while Bacteroidetes and Euryarchaeota inversely correlated with TLR7‐mediated immune activation. Specific types of fecal microbiome abundance (e.g. Alistipes putredinis) positively correlated with HIV rebound. In conclusion, variability in the composition of the fecal microbiome is associated with markers of immune activation following vesatolimod treatment and ART interruption.

HIV-1 rebound after anti-retroviral therapy

Genetic Characterization Of Rebounding Hiv-1 After Cessation Of Highly Active Antiretroviral Therapy

Research progress on HIV latency-reversing agents and its mechanism

Viral rebound occurrence immediately after drug discontinuation involving neither drug resistance nor latent reservoir

Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound

Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion

The cell biology of HIV-1 latency and rebound

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy

Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy

A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients

The multifaceted nature of HIV tissue reservoirs

Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.

HIV rebound in HIV controllers is associated with a specific fecal microbiome profile

Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

Research Progress on Human Immunodeficiency Virus Type 1 Latent Infection Activator

Comparing HIV viral load assays and frequency of low level virological rebound in clinical practice

The reservoir of latent HIV